Healthcare / BiotechnologyTokyo
$21.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-815.3M · quality 58.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-111.8%
↓Gross Margin
-1.7%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-13.4%
FCF CAGR
—
FCF margin
-108.7%
FCF / Net income
1.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $750.0M · net income $-815.3M · FCF $-815.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $750.0M | $750.0M | $610.1M | $1.13B | $1.15B |
| Net Income | $-815.3M | $-815.3M | $-1.29B | $-1.12B | $-2.57B |
| EBITDA | $-811.9M | $-811.9M | $-1.29B | $-1.12B | $-2.04B |
| EPS | -3.12 | -3.12 | -6.05 | -5.81 | -13.72 |
| Gross Margin | -1.7% | -1.7% | -29.1% | 3.7% | 9.9% |
| Operating Margin | -106.4% | -106.4% | -183.7% | -97.5% | -177.9% |
| Net Margin | -108.7% | -108.7% | -211.1% | -98.6% | -222.9% |
| Balance Sheet | |||||
| Current Ratio | 13.66 | 13.66 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-815.3M | $-815.3M | $-1.23B | $-800.3M | $-2.53B |
| Returns | |||||
| ROE | -111.8% | -111.8% | -364.2% | -130.8% | -129.9% |
| Valuation | |||||
| P/B | 7.52 | 7.52 | 11.43 | 9.69 | 6.72 |
| Growth & Yield | |||||
| Revenue Growth | 22.9% | 22.9% | -46.2% | -1.6% | — |
| EPS Growth | 48.4% | 48.4% | -4.1% | 57.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-12.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-6.05 → -3.12
Residual
-12.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.